Barclays Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $8
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Barclays analyst Etzer Darout initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Overweight rating and announces Price Target of $8.
Barclays analyst Etzer Darout initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Overweight rating and announces Price Target of $8.